Vical Incorporated (VICL), the development of paradigm-changing DNA vaccines and cancer immunotherapies biopharmaceutical firm, just reported the failure of the rusult of Phase3 trial of Melanoma therapy Allovectin which is the most advance product to cure the cancer. The fail trial makes Vical share tumble over 56% and trading at $1.57 per share today. The Vaccine didn't meet the survival endpoint so Vical will stop to develop the cancer therapy Allovectin and will focusing on other infectious disease vaccine program. Vical still has 2 more vaccine programs which are herpes simplex virus (HSV) and cytomegalovirus (CMV) but it didn't enter to clinical trial yet. Too bad that the Allovectin fail otherwise the cancer patient won't have to go through the chemotherapy and use this vaccine instead. Oh well, I still think that Vical still be a good company to invest since its has some other develop products on its list to go on the trial.